logo
Takeda’sZasocitinibSignificantlyOutperformsDeucravacitinibinHead-to-HeadPhase3PsoriasisStudy,PromisingtoRedefineOralTreatmentExpectations
===2026/6/12 9:58:16===
hetti A, Hautamaki EL. Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study. Psoriasis (Auckl). 2014;5:1-7. Published 2014 Dec 23. doi:10.2147/PTT.S74906

Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073-1113. doi:10.1016/j.jaad.2018.11.058.

Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 221;397(10281):1301-1315. doi:10.1016/S0140-6736(20)32549-6.

Gooderham MJ, Papp KA, Lynde CW. Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111-1119. doi:10.1111/jdv.14868

Muromoto R, Oritani K, Matsuda T. Current understanding of the role of tyrosine kinase 2 signaling in immune responses. World J Biol Chem. 2022;13(1):1&nda
=*=*=*=*=*=
当前为第16/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页